

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) Use of a pharmaceutical composition comprising a cytotoxic drug and a porous carrier material in the preparation of a medicament for the intra-tumoural delivery of a cytotoxic drug in a method of treating a cancer by chemo-brachytherapy.

2. (currently amended) Use according to claim 1 wherein the porous carrier material is doped or undoped silicon, germanium, silicon carbide or silicon nitride.

3. (currently amended) Use according to claim 1 or claim 2 wherein the porous carrier material is silicon.

4. (currently amended) Use according to claim 3 wherein the silicon is resorbable.

5. (currently amended) Use according to claim 4 where the resorbable silicon is mesoporous.

6. (currently amended) Use according to any preceding claim 1 wherein a cytotoxic drug is incorporated into the pores of the porous carrier material.

7. (currently amended) Use according to ~~any preceding claim 1~~ wherein the cytotoxic drug is present in an amount of from 15% to 85% by weight, based on the weight of the composition.

8. (currently amended) Use according to ~~any preceding claim 1~~ wherein the cytotoxic drug is selected from chlorambucil and paclitaxel.

9. (currently amended) Use according to ~~any preceding claim 1~~ wherein the pharmaceutical composition comprises a multiplicity of microparticles.

10. (original) Use of a porous carrier material in the preparation of a medicament for intra-tumoural delivery of a cytotoxic agent.

11. (original) A method of treating a cancer by chemo-brachytherapy comprising intra-tumoural administration of a pharmaceutical composition comprising a cytotoxic drug and a porous carrier material.

12. (currently amended) A method according to claim 11 wherein the pharmaceutical composition is as defined in ~~any of claims 1 to 9 above~~.

13. (original) Use of a porous carrier material having a cytotoxic drug incorporated into the pores thereof to delivery a cytotoxic drug at a dose higher than the LD50 of the corresponding free drug in a method of treating a cancer.

14. (original) Use according to claim 13 wherein the cytotoxic drug is selected from chlorambucil and paclitaxel.

15. (original) Use of chlorambucil in the manufacture of a medicament for the treatment of a cancer by chemo-brachytherapy.

16. (original) Use of a pharmaceutical composition comprising a porous carrier material and a cytotoxic drug selected from chlorambucil and paclitaxel in the manufacture of a medicament for the treatment of a cancer by chemo-brachytherapy.

17. (original) Use of a porous carrier material to deliver a cytotoxic drug selected from chlorambucil and paclitaxel in a method of treating a cancer by chemo-brachytherapy.

18. (original) A method for treating a cancer by chemo-brachytherapy comprising introducing to the site at which the cancer is located a pharmaceutical composition comprising a porous carrier material and a cytotoxic agent selected from chlorambucil and paclitaxel.

19. (currently amended) A method according to claim 18 wherein the porous carrier material is silicon.

20. (currently amended) A method according to claim 18 or claim 19 wherein the pharmaceutical composition is introduced to the site at which the cancer is located by injecting a suspension of microparticles into an artery or vein connected to or located in the organ in which the cancer tumour is located.

21. (currently amended) A method according to claim 18 or claim 19 wherein the pharmaceutical composition is introduced to the site at which the cancer is located by injecting a suspension of microparticles into the cancer tumour.